Drugs / BAT8007
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05879627 | Jan 2023 → Aug 2025 | cancer | Bio-Thera Solutions | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAT8007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05879627 ↗ |
| Modality | Monoclonal antibody | “anti Nectin-4 monoclonal antibody” NCT05879627 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT05879627 ↗ |